Jay Kranzler
Chairman presso AVENUE THERAPEUTICS, INC.
Patrimonio netto: 1 310 $ in data 31/03/2024
Profilo
Jay D.
Kranzler is the founder of Sequel Therapeutics, Inc. (founded in 1992) and Glytec Corp.
(founded in 1989).
He held the title of President & Chief Executive Officer at Sequel Therapeutics, Inc. and President & Chief Executive Officer at Glytec Corp.
Dr. Kranzler is also the founder of Perception Neuroscience, Inc. Dr. Kranzler's current job(s) include Chief Executive Officer & Director at Regenovation, Inc., Chairman at Avenue Therapeutics, Inc., Director at ImmunoBrain Checkpoint Ltd., Chief Medical Officer & Director at Pastorus, Inc., and Director at Baergic Bio, Inc. Dr. Kranzler's former job(s) include Chairman & Chief Executive Officer at Cypress Bioscience, Inc. (1996-2011), President, Chief Executive Officer & Director at Cytel Corp.
(1989-1995), Chairman at MSI Methylation Sciences, Inc., Vice President at Pfizer Inc., and Professor at the University of California San Diego.
Dr. Kranzler's education history includes a doctorate degree from Yale University and an undergraduate degree from Yeshiva University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 09/01/2024 | 8 911 ( 0.02% ) | 1 310 $ | 31/03/2024 |
Posizioni attive di Jay Kranzler
| Società | Posizione | Inizio |
|---|---|---|
| AVENUE THERAPEUTICS, INC. | Chairman | 07/03/2023 |
Regenovation, Inc.
 Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | Chief Executive Officer | - |
ImmunoBrain Checkpoint Ltd.
 ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | Director/Board Member | - |
Pastorus, Inc.
 Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | Chief Tech/Sci/R&D Officer | - |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Director/Board Member | - |
Precedenti posizioni note di Jay Kranzler
| Società | Posizione | Fine |
|---|---|---|
Cypress Bioscience, Inc.
 Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Chief Executive Officer | 01/02/2011 |
| Cytel Corp. | Chief Executive Officer | 01/08/1995 |
| Glytec Corp. | Chief Executive Officer | 02/01/1990 |
Perception Neuroscience, Inc.
 Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Chief Executive Officer | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Jay Kranzler
| Yale University | Doctorate Degree |
| Yeshiva University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Health Technology |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
Sequel Therapeutics, Inc.
 Sequel Therapeutics, Inc. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Sequel Therapeutics, Inc. is a private company that develops immunotherapeutic vaccines. The company is based in San Diego, CA. The company was founded by Jay D. Kranzler. Sequel Therapeutics was acquired by Epimmune, Inc. from The Scripps Research Institute on October 18, 1995 for $6.90 million. | Health Technology |
| Cytel Corp. | |
| Glytec Corp. | |
Regenovation, Inc.
Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | Commercial Services |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Health Services |
Pastorus, Inc.
Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | Health Technology |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Jay Kranzler
